Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rapport Therapeutics (Nasdaq: RAPP) announced management will present at the 44th Annual J.P.
Rhea-AI Summary
Rapport Therapeutics (Nasdaq: RAPP) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST / 2:15 p.m. EST. A live and archived webcast of the presentation will be available in the Investors section of the company website.
Investors can access the webcast at https://investors.rapportrx.com for live viewing and later replay.
Positive
- None.
Negative
- None.
Details
News Market Reaction – RAPP
In the Dec 18 session, RAPP gained 3.35%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference edition
- 44th
- 44th Annual J.P. Morgan Healthcare Conference
- Presentation date
- January 14, 2026
- Scheduled J.P. Morgan Healthcare Conference presentation
- Presentation time PST
- 11:15 a.m. PST
- J.P. Morgan Healthcare Conference slot
- Presentation time EST
- 2:15 p.m. EST
- J.P. Morgan Healthcare Conference slot
Historical Context
-
Strong Phase 2a RAP-219 efficacy and tolerability data in focal onset seizures.
-
Announcement of upcoming detailed RAP-219 Phase 2a presentations at AES.
-
Q3 financials, positive RAP-219 topline data, and capital raise details.
-
Planned participation in Stifel and Jefferies healthcare investor conferences.
-
Planned fireside chat at TD Cowen’s neuropsychiatry & epilepsy summit.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST.
A live and archived webcast of the presentation will be available in the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.